COMMUNIQUÉS West-GlobeNewswire

ATW Tech Provides Additional Information Regarding Signature of a Letter of Intent for Major Acquisition of Greywolf Entertainment Group
16/11/2018
MONTREAL, Nov. 16, 2018 (GLOBE NEWSWIRE) -- ATW Tech Inc. (“ ATW Tech ”) (TSX-V: ATW) has, as previously announced on November 6, 2018, signed a letter of intent for the acquisition from Fastrack Trust (the “ Trust ”) [...]
ATW Tech fournit de l’information additionnelle sur la signature de la lettre d’intention pour l’acquisition majeure du Groupe Greywolf Entertainement
16/11/2018
MONTRÉAL, 16 nov. 2018 (GLOBE NEWSWIRE) -- ATW Tech Inc. (« ATW Tech ») ( TSX-V : ATW ), a signé, tel qu’annoncé le 6 novembre 2018, une lettre d’intention visant l’acquisition de la totalité des actions de 6855318 [...]
Lifestyle Brand Weekend Unlimited Expanding Into Key US, Foreign Markets -- CFN Media
16/11/2018
SEATTLE, Nov. 16, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an [...]
Menlo Therapeutics to Participate in the 30th Annual Piper Jaffray Healthcare Conference
16/11/2018
REDWOOD CITY, Calif., Nov. 16, 2018 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus associated [...]
Aurora Spine Announces Exclusive Patent License Agreement for MIS SI Joint Product
16/11/2018
CARLSBAD, Calif., Nov. 16, 2018 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (TSXV:ASG) ("Aurora Spine" or the "Company") announced today that it has acquired an exclusive license to US patent #9,451,986 titled “ [...]
Dragon Jade Announces Filing of Registration Statement for Proposed Registered Offering
16/11/2018
HONG KONG, Nov. 16, 2018 (GLOBE NEWSWIRE) -- Dragon Jade International Limited (“Dragon Jade” or “the Company”) (OTCQX: DGJI), a provider of premier products and services, today notes that it has filed a registration [...]
Novartis receives positive CHMP opinion to expand Kisqali® combination therapy to all women with HR+/HER2- locally advanced or metastatic breast cancer
16/11/2018
Kisqali is the CDK4/6 inhibitor with the largest body of first-line evidence demonstrating consistent, superior and sustained efficacy vs. endocrine therapy alone[1] CHMP opinion is supported by two pivotal Phase III [...]
Progressive Care Inc. Announces Record-Breaking October 2018
16/11/2018
MIAMI, Nov. 16, 2018 (GLOBE NEWSWIRE) -- Progressive Care Inc. ( OTCQB: RXMD ), a personalized healthcare services and technology company, today announced further growth year-over-year in revenue and record-breaking [...]
Neon Therapeutics Named a Top Place to Work in Massachusetts by The Boston Globe
16/11/2018
CAMBRIDGE, Mass., Nov. 16, 2018 (GLOBE NEWSWIRE) -- Neon Therapeutics (Nasdaq: NTGN) has been named one of the top places to work in Massachusetts by The Boston Globe , an honor awarded based on employee feedback. The [...]
Imprimis Pharmaceuticals Ranked 88th Fastest Growing Company in North America on Deloitte’s 2018 Technology Fast 500™
16/11/2018
Imprimis attributes growth to its vision of making sure patients have access to high quality affordable medications SAN DIEGO, Nov. 16, 2018 (GLOBE NEWSWIRE) -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) today [...]
Stemline Therapeutics Announces Oral Presentation of SL-701 Phase 2 Data in Second-Line Glioblastoma at the 23rd Annual Meeting of the Society of Neuro-Oncology (SNO)
16/11/2018
NEW YORK, Nov. 16, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a biopharmaceutical company focused on the development and potential commercialization of novel oncology therapeutics, announced [...]
Sanofi: European Medicines Agency recommends fexinidazole, the first all-oral treatment for sleeping sickness
16/11/2018
European Medicines Agency recommends fexinidazole, the first all-oral treatment for sleeping sickness The positive opinion is the result of a 10-year partnership between the Drugs for Neglected Diseases initiative (DND [...]
Sanofi : L'Agence européenne des médicaments recommande l'approbation du fexinidazole, le premier traitement entièrement par voie orale de la maladie du sommeil
16/11/2018
L'Agence européenne des médicaments recommande l'approbation du fexinidazole, le premier traitement entièrement par voie orale de la maladie du sommeil L'avis favorable de l'EMA est l'aboutissement d'une collaboration [...]
BeiGene Announces Preliminary Clinical Data on PARP Inhibitor Pamiparib Presented at Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
16/11/2018
CAMBRIDGE, Mass., and BEIJING, China, Nov. 16, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative [...]
BioCryst Presents Data Highlighting the Rapid and Sustained Plasma Concentrations of BCX7353 in HAE Patients at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology
16/11/2018
RESEARCH TRIANGLE PARK, N.C., Nov. 16, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today presented data showing that an oral formulation of BCX7353 was rapidly absorbed and exhibited a long [...]
Agios Presents Updated Data from Phase 1 Dose-Escalation Study of AG-881 in Patients with IDH Mutant Positive Advanced Glioma
16/11/2018
– Median Treatment Duration of 15 Months Observed in Non-Enhancing Glioma with 13 Patients Remaining on Treatment Provides Evidence of Prolonged Disease Control – – Favorable Safety Profile at 10 mg and 50 mg, Doses [...]
VBL Therapeutics Presents Results from Phase 3 GLOBE Study in Patients with Recurrent Glioblastoma at the 2018 Society for Neuro-Oncology Annual Meeting
16/11/2018
Additional Analyses Provide Insight into Treatment Effect of VB-111 TEL AVIV, Israel, Nov. 16, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), is reporting results today from its Phase 3 GLOBE study in [...]
AGM Statement
16/11/2018
DXS INTERNATIONAL PLC AGM Statement The Board of DXS International plc (the “Company”), the NEX quoted clinical decision support developer and supplier of clinical decision support systems is pleased to confirm that at [...]
Fennec Pharmaceuticals Announces Scientific Symposium on Ototoxicity in Pediatric Cancer Patients at the 50th Congress of the International Society of Pediatric Oncology (SIOP) 2018 Meeting
16/11/2018
RESEARCH TRIANGLE PARK, N.C., Nov. 16, 2018 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK TM (a unique formulation of [...]

Pages